33 results for Ai9
33 results for Ai9
Ai9-SauSpyCas9 mouse - Model System  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Ai9 mouse - Model System  - [In Vivo] [Small Animal Testing Center (SATC), DCC, Delivery Systems Initiative] [Mouse]
|
Ai9 SaCas9 Guide A - Guide  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Ai9 SaCas9 Guide B - Guide  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Ai9 mouse immortalized fibroblasts - Model System  - [In Vitro] [Delivery Systems Initiative] [Mouse] |
Ai9 mouse (BCM) - Model System  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
HEK-293T with Ai9 transient reporter assay - Model System  - [In Vitro] [Delivery Systems Initiative] [Human] |
Cre Recombinase dose escalation study in Ai9 mice - Experiment  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
Testing gRNA sequence and gRNA scaffold modified in Ai9 mice. - Experiment  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
[Validation] Validation for Gao Delivery Team: Testing ssAAV5 delivered intratracheally for editing activity in lung epithelia in Ai9 mice - Experiment  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Selection of gRNA sequences and gRNA scaffold modification lead to improved editing of the Ai9 locus in vitro - Experiment  - [In Vitro] [Delivery Systems Initiative] [Mouse] |
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to sgRNA ratio (CMV promoter) - Experiment  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to sgRNA ratio (CB promoter) - Experiment  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9 to sgRNA ratio (CMV promoter) - Experiment  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to sgRNA ratio (CMV promoter) and self complementary sgRNA vector. - Experiment  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
Other Id:
A21202
Invitrogen, Donkey anti-mouse alexafluor 488 |
Other Id:
13-0300Â
Thermo-Fisher, Rat anti-GFAP |
Other Id:
ab104224Â
Abcam, mouse anti-NeuN |
RNP-NC-no ligand - Delivery System  - [In Vivo] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse] |
RNP-NC-RVG - Delivery System  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Ai14 gRNA - Guide  - [In Vivo] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse] |
SauCas9 - Genome Editor  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
AAVcc47-SaCas9-Ai9 - Vector  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain. - Experiment  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
sNLS-SpCas9-sNLS - Genome Editor  - [In Vivo] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse] |
Ai14 mouse - Model System  - [In Vivo] [Delivery Systems Initiative] [Mouse] |
Other Id:
Rockland Cat# 600-401-379
Anti-RFP (RABBIT) Antibody |
Other Id:
A21207
Invitrogen, Donkey anti-rabbit alexa fluor 594 |
[Validation] Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to mouse brain - Experiment  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
RNP-NC-CPP - Delivery System  - [In Vivo] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse] |
Other Id:
ab150155
Abcam, Donkey anti-rat alexa fluour 647 |
[Validation] Validation for Asokan Delivery Team: Evolving High Potency AAV Vectors for Neuromuscular Genome Editing. - Experiment  - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Ai14 mouse (congenic) - Model System  - [In Vivo] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse]
|
33 results for Ai9
Category | Type | Name | Description | Last Updated Date | View Associated.. |
---|---|---|---|---|---|
Model System | Animal | Ai9-SauSpyCas9 mouse | Ai9-SauSpyCas9 is a version of Ai9 that has a single guide RNA sites on both sides of the STOP cassette. This is a Cre reporter allele that has a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. Ai9 mice express robust tdTomato fluorescence following Cre-mediated recombination. | ||
Model System | Animal | Ai9 mouse | Ai9 mouse has a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. |
|
|
Guide | Ai9 SaCas9 Guide A | This gRNA targets the Ai9 and related transgenes | |||
Guide | Ai9 SaCas9 Guide B | This gRNA targets the Ai9 and related transgenes | |||
Model System | Cell | Ai9 mouse immortalized fibroblasts | Immortalized fibroblasts made from Ai9 (B6.Cg-Gt(ROSA)26Sor^tm9(CAG-tdTomato)Hze/J) mice | ||
Model System | Animal | Ai9 mouse (BCM) | Ai9 mouse has a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. | ||
Model System | Cell | HEK-293T with Ai9 transient reporter assay | HEK-293T cells transfected with an Ai9 inducible transgene reporter plasmid used to test gene editing activity by fluorescence | ||
Experiment | In Vivo | Cre Recombinase dose escalation study in Ai9 mice | A single stranded cmv cre cassette was packaged into AAV9 or AAVcc47 and injected intravenously in Ai9 mice. We injected n=3 at three different doses (1e10, 1e11, 1e12 vg) and harvested organs 4 weeks post injection. Fluorescence intensity in liver, heart, and skeletal muscle was quantified with tiff based images in Image J and neuronal transduction from each vector was quantified at the 1e12vg dose by counting the number of tdTomato+ neurons and number of NeuN+ cells from multiple sections and images. | 2021-09-16 | |
Experiment | In Vivo | Testing gRNA sequence and gRNA scaffold modified in Ai9 mice. | 3e11 vg/mouse of AAV-BI28:GFAP-SaCas9-WPRE-pA and 3e11 vg/mouse of AAV-BI28:GFAP-NLS-GFP-U6-L1-U6-R2 were codelivered intravenously to adult male and female Ai9 mice. Editing was assessed in brain sections 4 weeks later. | 2021-04-17 | |
Experiment | In Vivo | Validation for Gao Delivery Team: Testing ssAAV5 delivered intratracheally for editing activity in lung epithelia in Ai9 mice | AAV5 encoding CRISPR/Cas editing machinery were delivered to the lungs of reporter mice by intratracheal instillation. After 4 weeks incubation, the mice were dissected and the lungs imaged for the presence of tdTomato fluorescence, indicating successful editing. Editing calculated by dividing the number of tdTomato+ red cells by the number of nuclei in each airway | 2021-03-30 | |
Experiment | In Vitro | Selection of gRNA sequences and gRNA scaffold modification lead to improved editing of the Ai9 locus in vitro | Reporter transgene activation by SaCas9 gRNA target and modified scaffold sequences by transient transfection in immortalized Ai9 mouse fibroblasts | 2021-04-17 | |
Experiment | In Vivo | Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to sgRNA ratio (CMV promoter) | A dual vector strategy was employed: one delivering two single guide RNAs targeting the Rosa26 locus and one delivering CMV driven SaCas9 (both single stranded AAV cassettes). This strategy was evaluted with both AAV9 (n=3) and AAVcc47 (n=3) by intravenous injection in Ai9 mice. A total dose of 3e12vg was injected into each mouse (1.5e12vg each vector mixed 1:1) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart. | 2021-09-16 | |
Experiment | In Vivo | Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to sgRNA ratio (CB promoter) | A dual vector strategy was employed: one delivering a single guide RNA and CB driven SaCas9, and another delivering the second guide RNA and CB driven SaCas9. This strategy was evaluted with both AAV9 (n=4) and AAVcc47 (n=5) by intravenous injection in Ai9 mice. A total dose of 2e12vg was injected into each mouse (1e12vg each vector mixed 1:1) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart. | 2021-09-16 | |
Experiment | In Vivo | Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9 to sgRNA ratio (CMV promoter) | A dual vector strategy was employed: one delivering two single guide RNAs targeting the Rosa26 locus and one delivering CMV driven SaCas9 (both single stranded AAV cassettes). This strategy was evaluted with both AAV9 (n=4) and AAVcc47 (n=5) by intravenous injection in Ai9 mice. A total dose of 4e12vg was injected into each mouse and vectors mixed in a 1:4 ratio of cas9 to guide RNA (1e12vg of CMV Sacas9 vector and 3e12vg of the sgRNA vector) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart. | 2021-09-16 | |
Experiment | In Vivo | Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to sgRNA ratio (CMV promoter) and self complementary sgRNA vector. | A dual vector strategy was employed: one self complementary vector delivering two single guide RNAs targeting the Rosa26 locus and one delivering CMV driven SaCas9 (single stranded vector). This strategy was evaluted with both AAV9 (n=4) and AAVcc47 (n=4) by intravenous injection in Ai9 mice. A total dose of 4e12vg was injected into each mouse and vectors mixed in a 1:1 ratio of cas9 to guide RNA (2e12vg of CMV Sacas9 vector and 2e12vg of the self complementary sgRNA vector) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart. | 2021-09-16 | |
Antibody | AB_141607 | Invitrogen, Donkey anti-mouse alexafluor 488 | |||
Antibody | AB_2532994 | Thermo-Fisher, Rat anti-GFAP | |||
Antibody | AB_10711040 | Abcam, mouse anti-NeuN | |||
Delivery System | Nanoparticle | RNP-NC-no ligand | The nanocapsule is a thin glutathione (GSH)-cleavable covalently crosslinked polymer coating around a preassembled ribonucleoprotein (RNP) complex between a Cas9 nuclease and an sgRNA. | ||
Delivery System | Nanoparticle | RNP-NC-RVG | The nanocapsule is a thin glutathione (GSH)-cleavable covalently crosslinked polymer coating around a preassembled ribonucleoprotein (RNP) complex between a Cas9 nuclease and an sgRNA. This nanoparticle has an addition of a RVG peptide YTIWMPENPRPGTPCDIFTNSRGKRASNG which specifically interacts withthe N-acetylecholine receptor (AchR) on neuronal cells, which mediates NP entry | ||
Guide | Ai14 gRNA | This sgRNA targets the Ai9 and related transgenes at multiple sites | |||
Genome Editor | Cas Nuclease | SauCas9 | |||
Vector | Viral Vector | AAVcc47-SaCas9-Ai9 | AAV2/9 expressing SaCas9 and single sgRNA under U6 promoter | ||
Experiment | In Vivo | Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain. | Nanocapusules carrying CRISPR Cas9 RNP with guide RNA targeting the stop sequence in the Ai14 transgene are intracerebrally delivered to Ai14 mice and gene editing is measured by gain of tdTomato protein expression. | 2020-10-28 | |
Genome Editor | Cas Nuclease | sNLS-SpCas9-sNLS | SpCas9 with N- and C-terminal SV40 NLS | ||
Model System | Animal | Ai14 mouse | Ai14 mouse has a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. The att site flanked neo selection cassette has been removed in this strain. | ||
Antibody | AB_2209751 | Anti-RFP (RABBIT) Antibody | |||
Antibody | AB_141637 | Invitrogen, Donkey anti-rabbit alexa fluor 594 | |||
Experiment | In Vivo | Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to mouse brain | Delivery of CRISPR/Cas9 via RNP-loaded nanocages to the brain in Ai14 mice | 2021-04-01 | |
Delivery System | Nanoparticle | RNP-NC-CPP | The nanocapsule is a thin glutathione (GSH)-cleavable covalently crosslinked polymer coating around a preassembled ribonucleoprotein (RNP) complex between a Cas9 nuclease and an sgRNA. This nanoparticle has an addition of a cell penetrating peptide (CPP) from the TAT peptide (GRKKRRQRRRPQ) which lacks cell-type specficity | ||
Antibody | AB_2813835 | Abcam, Donkey anti-rat alexa fluour 647 | |||
Experiment | In Vivo | Validation for Asokan Delivery Team: Evolving High Potency AAV Vectors for Neuromuscular Genome Editing. | Quantification of CRISPR/Cas editing in liver and heart following custom AAV-mediated delivery. Detection of editing in non-target tissues. | 2021-03-30 | |
Model System | Animal | Ai14 mouse (congenic) | Ai14 mouse has a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. The att site flanked neo selection cassette has been removed in this strain. |
|